Physician profile
Fatima Ajaz
NPI 1477731461
$6,375.84
in general payments reported to CMS, 2019-2025
26 companies · $739 in 2025
The $739 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $142 · 2021: $389 · 2022: $2,044 · 2023: $1,433 · 2024: $1,629 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,352 · Education: $449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,352.21 |
| Education | $448.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $965.72 | 2021-2025 | Tezspire, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $888.31 | 2020-2025 | Nucala, Trelegy Ellipta |
| Medtronic, INC. | $782.79 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $492.34 | 2021-2025 | Opsumit, Uptravi |
| United Therapeutics Corporation | $412.38 | 2022-2025 | Tyvaso, Orenitram, Remodulin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $375.55 | 2020-2025 | Ofev, Stiolto Respimat |
| Baxter Healthcare | $288.84 | 2022-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Electromed, INC. | $277.16 | 2021-2025 | Smartvest |
| Regeneron Healthcare Solutions, INC. | $272.79 | 2020-2024 | Dupixent |
| Genzyme Corporation | $192.65 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $191.45 | 2022-2024 | |
| Insmed, INC. | $162.15 | 2021-2025 | Arikayce |
| Mylan Specialty L.P. | $148.49 | 2022-2024 | Yupelri |
| Grifols USA, LLC | $136.02 | 2020-2024 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $119.46 | 2023-2025 | Winrevair, Zerbaxa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $110.66 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $94.33 | 2024-2025 | Glassia |
| Philips North America LLC | $94.03 | 2023-2024 | (Ak6) Vest Therapy |
| Amgen INC. | $85.11 | 2022-2024 | Tavneos, Tezspire |
| Genentech USA, INC. | $78.95 | 2022-2025 | Xolair |
| Pfizer INC. | $61.68 | 2023 | |
| Vifor Pharma, INC. | $56.14 | 2024-2025 | Zemaira |
| Novartis Pharmaceuticals Corporation | $32.81 | 2023 | |
| Advanced Respiratory, INC | $19.99 | 2021 | |
| Viatris Specialty LLC | $18.18 | 2025 | Yupelri |
| Pinnacle Biologics, INC | $17.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fatima Ajaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.